BriaCell Therapeutics Corp Warrant
BCTXW
BCTXW was delisted on the 26th of February, 2026.
4 hedge funds and large institutions have $121K invested in BriaCell Therapeutics Corp Warrant in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0.06% more ownership
Funds ownership: 2.82% → 2.88% (+0.06%)
80% less capital invested
Capital invested by funds: $609K → $121K (-$488K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$7.21K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $101K | – | – | – |
|
|
RAM
2
Redmond Asset Management
Henrico,
Virginia
| $17.2K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $2.7K | +$7.21K | +10,023 | New |
|
4
Osaic Holdings
Scottsdale,
Arizona
| $184 | – | – | – |
|
BCTXW Hedge Fund Activity: Q2 2024 in Review
4 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Corp Warrant (BCTXW) for Q2 2024, worth a combined $121K — down 80% from $609K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BCTXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $7.21K.
- 4 institutional investors held BriaCell Therapeutics Corp Warrant (BCTXW) as of Q2 2024, up from 3 in Q1 2024.
- Funds reported $121K of BriaCell Therapeutics Corp Warrant stock for Q2 2024, down 80% quarter-over-quarter.
- 1 fund opened new BriaCell Therapeutics Corp Warrant positions in Q2 2024 and 0 closed out, a net change of +1 holder.
- The largest BriaCell Therapeutics Corp Warrant buyer in Q2 2024 was UBS Group, an estimated $7.21K added.
Based on aggregated 13F filings for Q2 2024.